Anthony Andrasfay
Keine laufenden Positionen mehr
Profil
Anthony Andrasfay is Vice President of Clinical Operations for Cardium Therapeutics, Inc., which he joined in November 2005.
He was an Associate Director of Clinical Research for Idun Pharmaceuticals, Clinical Research Manager of Collateral Therapeutics from 1999 to 2003, Project Manager of Clinical Development for Dura Pharmaceuticals, Inc. from 1996 to 1999 and Manager of Clinical Research for Gensia, Inc. from 1992 to 1996.
Mr. Andrasfay received a BS in Biological Sciences from the University of California, Irvine.
Ehemalige bekannte Positionen von Anthony Andrasfay
Unternehmen | Position | Ende |
---|---|---|
Cardium Therapeutics, Inc. /Old/ | Technik-/Wissenschafts-/F&E-Leiter | 23.01.2006 |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.01.2003 |
Dura Pharmaceuticals, Inc.
Dura Pharmaceuticals, Inc. BiotechnologyHealth Technology Dura Pharmaceuticals, Inc. markets and sells prescription products that treat infectious and respiratory diseases. Dura focuses on products and transactions that leverage its sales and marketing organization. Dura also intends, through the use of collaborative relationships, to develop the Spiros® motorized blisterdisk and Spiros® S2 pulmonary drug delivery systems for the local and systemic delivery of a wide range of medications. It is located in San Diego, CA. | Corporate Officer/Principal | 01.01.1999 |
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | Corporate Officer/Principal | 01.01.1996 |
Idun Pharmaceuticals, Inc.
Idun Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Ausbildung von Anthony Andrasfay
University of California, Irvine | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
GENE BIOTHERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Cardium Therapeutics, Inc. /Old/ | Commercial Services |
Idun Pharmaceuticals, Inc.
Idun Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA. | Health Technology |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Commercial Services |
Dura Pharmaceuticals, Inc.
Dura Pharmaceuticals, Inc. BiotechnologyHealth Technology Dura Pharmaceuticals, Inc. markets and sells prescription products that treat infectious and respiratory diseases. Dura focuses on products and transactions that leverage its sales and marketing organization. Dura also intends, through the use of collaborative relationships, to develop the Spiros® motorized blisterdisk and Spiros® S2 pulmonary drug delivery systems for the local and systemic delivery of a wide range of medications. It is located in San Diego, CA. | Health Technology |
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | Health Technology |